STERIS plc $STE Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC trimmed its position in STERIS plc (NYSE:STE) by 18.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,134 shares of the medical equipment provider’s stock after selling 9,449 shares during the quarter. Corient Private Wealth LLC’s holdings in STERIS were worth $10,745,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund acquired a new position in STERIS in the fourth quarter worth $25,000. Activest Wealth Management raised its holdings in shares of STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 89 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in shares of STERIS during the fourth quarter worth $28,000. Harbor Investment Advisory LLC lifted its position in shares of STERIS by 115.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 60 shares during the last quarter. Finally, Cornerstone Planning Group LLC lifted its position in shares of STERIS by 342.3% in the 4th quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 89 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on STE shares. Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Piper Sandler restated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. KeyCorp decreased their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

STERIS Stock Up 1.7%

STE stock opened at $206.68 on Thursday. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The company has a market capitalization of $20.14 billion, a price-to-earnings ratio of 26.06 and a beta of 0.93. The firm’s 50-day moving average is $213.19 and its two-hundred day moving average is $233.79. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the business earned $2.74 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Insider Activity

In related news, VP John Adam Zangerle sold 1,419 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the transaction, the vice president owned 35,259 shares of the company’s stock, valued at $7,379,003.52. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 3,054 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $214.64, for a total value of $655,510.56. Following the transaction, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at $13,956,107.44. This represents a 4.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,328 shares of company stock worth $1,554,051. 1.12% of the stock is owned by company insiders.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.